A Vanderbilt University-led research team has discovered a “master regulator” for cholesterol production and transport in the liver — a tiny piece of RNA called microRNA-223.

Vanderbilt investigators identify a new therapeutic target for the inflammatory lung disease sarcoidosis.

Imagine an inherited cause of early heart attacks that is more common than type-1 diabetes, multiple sclerosis or cystic fibrosis, but goes largely unrecognized.

The Tennessee Public Health Association and the Tennessee Medical Association are collaborating to establish the “William Schaffner, M.D., Public Health Hero Award,” to be presented annually to an individual who has demonstrated extraordinary efforts in the advancement of public health in Tennessee.

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.

In some cases, HDL, the "good cholesterol," may not function properly and may actually accelerate atherosclerosis.

Colorectal cancer is one of the leading causes of death among populations around the world. While diet, physical activity and other lifestyle factors can influence the risk of developing the disease, hereditary factors also play an important role.